Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR.

Lynn HuynhTodor I Totev Francis VekemanMaureen P NearyMei S DuhAl B Benson

Published in: Journal of medical economics (2017)

Symptom resolution/improvement of diarrhea/flushing after treatment with an above-standard dose of octreotide-LAR in NET was associated with a statistically significant healthcare cost decrease compared to a scenario of no symptom improvement.

Keyphrases

healthcare
single molecule
neuroendocrine tumors
case report
physical activity
sleep quality
depressive symptoms
clostridium difficile
health insurance